New insights into lipid metabolism in chronic kidney disease

Journal of Renal Nutrition

Volumn 21, Issue 1, 2011, Pages 120-123

  Kaysen, George A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Affairs Medical Center Sacramento   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; HUMAN; LIPID METABOLISM; METABOLISM; REVIEW;

HUMANS; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM;

DISCOIDAE;

EID: 78650698851     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.10.017     Document Type: Review

References (15)

1. Kaysen G.A. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 2009, 19:73-77.
2. Mekki K., Bouchenak M., Remaoun M., et al. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study. Med Sci Monit 2004, 10:CR439-CR446.
3. Lo J.C., Go A.S., Chandra M., et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007, 50:552-558.
4. Ikewaki K., Schaefer J.R., Frischmann M.E., et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2615-2622.
5. Dautin G., Soltani Z., Ducloux D., et al. Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int 2007, 72:871-878.
6. Chan D.T., Dogra G.K., Irish A.B., et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res 2009, 50:2524-2531.
7. Mekki K., Prost J., Remaoun M., et al. Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients. BMC Cardiovasc Disord 2009, 9:41.
8. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005, 16:1794-1802.
9. Yeun J.Y., Levine R.A., Mantadilok V., et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000, 35:469-476.
10. Kaysen G.A., Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004, 15:538-548.
11. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
12. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
13. Wanner C., Krane V., März W. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248. German Diabetes and Dialysis Study Investigators.
14. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
15. Ridker P.M., MacFadyen J., Cressman M., et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010, 55:1266-1273.